Zoledronic acid use in cancer patients

Robert Coleman, Richard Cook, Vera Hirsh, Pierre Major, Allan Lipton

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Bone is the most common site for metastasis from solid tumors, and the majority of patients will develop bone metastases during the natural course of their disease. Bisphosphonates are an effective treatment for preventing skeletal-related events in patients with bone metastases and may preserve functional independence and quality of life. Although several bisphosphonates have been investigated in patients with solid tumors, only zoledronic acid (ZOL) is approved by the US Food and Drug Administration and the European Medicines Agency for preventing skeletal-related events in patients across a broad range of solid tumors. In addition, bisphosphonates, notably ZOL, prevent cancer treatment-induced bone loss in breast and prostate cancer patients who are receiving endocrine therapy. It also has been demonstrated that ZOL directly and indirectly inhibits cancer cell growth in vitro and growth and tumorigenesis in animal model systems. These properties may produce clinically meaningful benefits. In recent clinical studies in patients with cancer, ZOL improved overall and prolonged disease-free survival. Ongoing clinical trials in patients with solid tumors will provide further insight into the potential of ZOL to prevent distant metastases and improve survival.

Original languageEnglish (US)
Pages (from-to)11-23
Number of pages13
JournalCancer
Volume117
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

zoledronic acid
Diphosphonates
Neoplasms
Neoplasm Metastasis
Bone and Bones
United States Food and Drug Administration
Growth
Disease-Free Survival
Prostatic Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Coleman, R., Cook, R., Hirsh, V., Major, P., & Lipton, A. (2011). Zoledronic acid use in cancer patients. Cancer, 117(1), 11-23. https://doi.org/10.1002/cncr.25529
Coleman, Robert ; Cook, Richard ; Hirsh, Vera ; Major, Pierre ; Lipton, Allan. / Zoledronic acid use in cancer patients. In: Cancer. 2011 ; Vol. 117, No. 1. pp. 11-23.
@article{52b200e27d8b460ba3dcbf3f5d37193f,
title = "Zoledronic acid use in cancer patients",
abstract = "Bone is the most common site for metastasis from solid tumors, and the majority of patients will develop bone metastases during the natural course of their disease. Bisphosphonates are an effective treatment for preventing skeletal-related events in patients with bone metastases and may preserve functional independence and quality of life. Although several bisphosphonates have been investigated in patients with solid tumors, only zoledronic acid (ZOL) is approved by the US Food and Drug Administration and the European Medicines Agency for preventing skeletal-related events in patients across a broad range of solid tumors. In addition, bisphosphonates, notably ZOL, prevent cancer treatment-induced bone loss in breast and prostate cancer patients who are receiving endocrine therapy. It also has been demonstrated that ZOL directly and indirectly inhibits cancer cell growth in vitro and growth and tumorigenesis in animal model systems. These properties may produce clinically meaningful benefits. In recent clinical studies in patients with cancer, ZOL improved overall and prolonged disease-free survival. Ongoing clinical trials in patients with solid tumors will provide further insight into the potential of ZOL to prevent distant metastases and improve survival.",
author = "Robert Coleman and Richard Cook and Vera Hirsh and Pierre Major and Allan Lipton",
year = "2011",
month = "1",
day = "1",
doi = "10.1002/cncr.25529",
language = "English (US)",
volume = "117",
pages = "11--23",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Coleman, R, Cook, R, Hirsh, V, Major, P & Lipton, A 2011, 'Zoledronic acid use in cancer patients', Cancer, vol. 117, no. 1, pp. 11-23. https://doi.org/10.1002/cncr.25529

Zoledronic acid use in cancer patients. / Coleman, Robert; Cook, Richard; Hirsh, Vera; Major, Pierre; Lipton, Allan.

In: Cancer, Vol. 117, No. 1, 01.01.2011, p. 11-23.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Zoledronic acid use in cancer patients

AU - Coleman, Robert

AU - Cook, Richard

AU - Hirsh, Vera

AU - Major, Pierre

AU - Lipton, Allan

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Bone is the most common site for metastasis from solid tumors, and the majority of patients will develop bone metastases during the natural course of their disease. Bisphosphonates are an effective treatment for preventing skeletal-related events in patients with bone metastases and may preserve functional independence and quality of life. Although several bisphosphonates have been investigated in patients with solid tumors, only zoledronic acid (ZOL) is approved by the US Food and Drug Administration and the European Medicines Agency for preventing skeletal-related events in patients across a broad range of solid tumors. In addition, bisphosphonates, notably ZOL, prevent cancer treatment-induced bone loss in breast and prostate cancer patients who are receiving endocrine therapy. It also has been demonstrated that ZOL directly and indirectly inhibits cancer cell growth in vitro and growth and tumorigenesis in animal model systems. These properties may produce clinically meaningful benefits. In recent clinical studies in patients with cancer, ZOL improved overall and prolonged disease-free survival. Ongoing clinical trials in patients with solid tumors will provide further insight into the potential of ZOL to prevent distant metastases and improve survival.

AB - Bone is the most common site for metastasis from solid tumors, and the majority of patients will develop bone metastases during the natural course of their disease. Bisphosphonates are an effective treatment for preventing skeletal-related events in patients with bone metastases and may preserve functional independence and quality of life. Although several bisphosphonates have been investigated in patients with solid tumors, only zoledronic acid (ZOL) is approved by the US Food and Drug Administration and the European Medicines Agency for preventing skeletal-related events in patients across a broad range of solid tumors. In addition, bisphosphonates, notably ZOL, prevent cancer treatment-induced bone loss in breast and prostate cancer patients who are receiving endocrine therapy. It also has been demonstrated that ZOL directly and indirectly inhibits cancer cell growth in vitro and growth and tumorigenesis in animal model systems. These properties may produce clinically meaningful benefits. In recent clinical studies in patients with cancer, ZOL improved overall and prolonged disease-free survival. Ongoing clinical trials in patients with solid tumors will provide further insight into the potential of ZOL to prevent distant metastases and improve survival.

UR - http://www.scopus.com/inward/record.url?scp=78650708531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650708531&partnerID=8YFLogxK

U2 - 10.1002/cncr.25529

DO - 10.1002/cncr.25529

M3 - Article

C2 - 21235033

AN - SCOPUS:78650708531

VL - 117

SP - 11

EP - 23

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -

Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients. Cancer. 2011 Jan 1;117(1):11-23. https://doi.org/10.1002/cncr.25529